Author

Veit Bücklein

Observed names: Buecklein, V., Bücklein, V.L., Bücklein, Veit, Bücklein, Veit L, Bücklein, Veit L., Bücklein, Veit Leonhard, V Bücklein, V. Buecklein, V. Bücklein, V. L. Buecklein, V. L. Bücklein, Veit Buecklein, Veit Bücklein, Veit L Buecklein, Veit L Bücklein, Veit L. Buecklein, Veit L. Bücklein, Veit Leonhard Buecklein, Veit Leonhard Bücklein, Veit Leonhardt Bücklein

Observed institutions: German Cancer Research Center, Leiden University Medical Center, Helmholtz Munich, LMU Klinikum, München Klinik, Beckman Coulter (United States), Deutsches Konsortium für Translationale Krebsforschung, Technical University of Munich, Ludwig-Maximilians-Universität München

ORCID: 0000-0001-7391-7280

Observed ORCID: 0000-0001-7391-7280

OpenAlex ID: A5041376830

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

2021 · Michael Heuser, Sylvie D. Freeman, et al. · Blood · 764

CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma

2021 · Kai Rejeski, Ariel Perez, et al. · Blood · 475

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals

2022 · Nora Philipp, Maryam Kazerani, et al. · Blood · 280

T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments

2021 · Naval Daver, Ahmad S. Alotaibi, et al. · Leukemia · 249

GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany

2022 · Wolfgang Andreas Bethge, Peter Martus, et al. · Blood · 214

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL

2022 · Kai Rejeski, Ariel Perez, et al. · Journal for ImmunoTherapy of Cancer · 202

Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed/refractory acute myeloid leukemia (R/R AML).

2020 · Farhad Ravandi, Roland B. Walter, et al. · Journal of Clinical Oncology · 104

Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

2019 · Marion Subklewe, Anthony Stein, et al. · Blood · 91

Application of blinatumomab, a bispecific anti-CD3/CD19 T-cell engager, in treating severe systemic sclerosis: A case study

2024 · Marion Subklewe, Giulia Magno, et al. · European Journal of Cancer · 89

Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality

2024 · Kai Rejeski, Yucai Wang, et al. · Blood Advances · 78

Virus infection in HLA-haploidentical hematopoietic stem cell transplantation: incidence in the context of immune recovery in two different transplantation settings

2015 · Johanna Tischer, Nicole Engel, et al. · Annals of Hematology · 76

2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party

2025 · Jacqueline Cloos, Peter J. M. Valk, et al. · Blood · 73

Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE

2021 · Patrick Schöffski, Michaela Kubickova, et al. · European Journal of Cancer · 69

Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy

2022 · Kai Rejeski, Andreas Burchert, et al. · Blood Advances · 67

Diagnosis of CLL revisited: increased specificity by a modified five‐marker scoring system including CD 200

2017 · Thomas Köhnke, Veronika K. Wittmann, et al. · British Journal of Haematology · 65

Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion

2023 · Kai Rejeski, Ariel Perez, et al. · Science Advances · 63

Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML

2023 · D. Nixdorf, M. Sponheimer, et al. · Leukemia · 62

CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany

2023 · Peter Bader, Claudia Rossig, et al. · Blood Advances · 61

Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy

2023 · Kai Rejeski, David M. Cordas dos Santos, et al. · Cancer Immunology Research · 56

Characterization of a Novel FLT3 BiTE Molecule for the Treatment of Acute Myeloid Leukemia

2020 · Bettina Brauchle, Rebecca L. Goldstein, et al. · Molecular Cancer Therapeutics · 56

Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy – a case report

2021 · Kai Rejeski, Wolfgang G. Kunz, et al. · BMC Infectious Diseases · 52

The CAR‐HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL

2023 · Kai Rejeski, Yucai Wang, et al. · American Journal of Hematology · 50

Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-cell treatment

2022 · Florian Schoeberl, Steffen Tiedt, et al. · Blood Advances · 48

Second haematopoietic SCT using HLA-haploidentical donors in patients with relapse of acute leukaemia after a first allogeneic transplantation

2014 · J Tischer, N Engel, et al. · Bone Marrow Transplantation · 48

Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies

2022 · David M. Cordas Dos Santos, Kai Rejeski, et al. · Haematologica · 46

Works count: 270

Citation count: 4,683

H-index: 35

I10-index: 66